表紙
市場調査レポート

肺高血圧症 - パイプライン分析

Pulmonary Hypertension - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 251597
出版日 ページ情報 英文 228 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
肺高血圧症 - パイプライン分析 Pulmonary Hypertension - Pipeline Review, H2 2015
出版日: 2015年11月30日 ページ情報: 英文 228 Pages
概要

肺高血圧症は、心臓から肺に走っている動脈の高血圧です。主な症状は、運動による息切れで、通常ゆっくり始まって、時間とともにひどくなります。他にも胸痛や疲労、無気力、突然の卒倒、脚の腫脹(浮腫)などが見られます。

当レポートでは、肺高血圧症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

肺高血圧症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Sanofi
  • Vectura Group plc
  • Bayer AG
  • Ikaria Inc.
  • Proreo Pharma AG
  • Vicore Pharma AB
  • Biolab Sanus Farmaceutica Ltda.
  • Hanmi Pharmaceuticals, Co. Ltd.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6831IDB

Summary

Global Markets Direct's, 'Pulmonary Hypertension - Pipeline Review, H2 2015', provides an overview of the Pulmonary Hypertension's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Hypertension
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pulmonary Hypertension and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pulmonary Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pulmonary Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pulmonary Hypertension Overview
  • Therapeutics Development
    • Pipeline Products for Pulmonary Hypertension - Overview
    • Pipeline Products for Pulmonary Hypertension - Comparative Analysis
  • Pulmonary Hypertension - Therapeutics under Development by Companies
  • Pulmonary Hypertension - Therapeutics under Investigation by Universities/Institutes
  • Pulmonary Hypertension - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Pulmonary Hypertension - Products under Development by Companies
  • Pulmonary Hypertension - Products under Investigation by Universities/Institutes
  • Pulmonary Hypertension - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • APT Therapeutics, Inc.
    • Arena Pharmaceuticals, Inc.
    • Asahi Kasei Pharma Corp.
    • Ascendis Pharma A/S
    • Bayer AG
    • Bial - Portela & Ca, S.A.
    • Biolab Sanus Farmaceutica Ltda.
    • Cardioxyl Pharmaceuticals, Inc.
    • Carolus Therapeutics, Inc.
    • Celsion Corporation
    • Complexa, Inc.
    • Corridor Pharmaceuticals Inc.
    • Cytokinetics, Inc.
    • Eli Lilly and Company
    • Gilead Sciences, Inc.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Insmed Incorporated
    • Kowa Company, Ltd.
    • Lacer, S.A.
    • LTT Bio-Pharma Co., Ltd.
    • Mezzion Pharma Co. Ltd.
    • miRagen Therapeutics, Inc.
    • Nippon Shinyaku Co., Ltd.
    • Novartis AG
    • Peloton Therapeutics, Inc.
    • PharmaIN Corporation
    • PhaseBio Pharmaceuticals, Inc.
    • Pluristem Therapeutics Inc.
    • Proteo, Inc.
    • Pulmokine, Inc.
    • Reata Pharmaceuticals, Inc.
    • Respira Therapeutics, Inc.
    • Sagene Pharmaceuticals, Inc.
    • Sanofi
    • Selten Pharma, Inc
    • Serodus ASA
    • Silence Therapeutics Plc
    • Sinoxa Pharma GmbH
    • SteadyMed Therapeutics, Inc.
    • Suda Ltd
    • Toray Industries, Inc.
    • VBS Pharmaceuticals
    • Vectura Group Plc
    • Vicore Pharma AB
  • Pulmonary Hypertension - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (allopurinol + apocynin) - Drug Profile
    • ambrisentan - Drug Profile
    • Antibody for Cancer and PAH - Drug Profile
    • Antibody for Pulmonary Arterial Hypertension - Drug Profile
    • APT-102 - Drug Profile
    • bardoxolone methyl - Drug Profile
    • BAY sGCact - Drug Profile
    • beraprost sodium ER - Drug Profile
    • beraprost sodium SR - Drug Profile
    • BIA-51058 - Drug Profile
    • BL-214 - Drug Profile
    • C-21 - Drug Profile
    • CAR Peptide - Drug Profile
    • CT-2009 - Drug Profile
    • CXA-10 - Drug Profile
    • Drug for Pulmonary Hypertension - Drug Profile
    • Drug for Pulmonary Hypertension - Drug Profile
    • Drugs to Antagonize Notch Receptor 3 for Pulmonary Arterial Hypertension - Drug Profile
    • fasudil - Drug Profile
    • HGP-1207 - Drug Profile
    • imatinib mesylate - Drug Profile
    • INS-1009 - Drug Profile
    • LA-419 - Drug Profile
    • lisuride - Drug Profile
    • macitentan - Drug Profile
    • MFC-001 - Drug Profile
    • MFC-002 - Drug Profile
    • Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - Drug Profile
    • Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile
    • Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile
    • Oligonucleotide to Inhibit miR-145 for PAH - Drug Profile
    • P-2pal18S - Drug Profile
    • PB-1046 - Drug Profile
    • PB-1120 - Drug Profile
    • Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile
    • PGC-VIP - Drug Profile
    • pitavastatin NP - Drug Profile
    • PK-10453 - Drug Profile
    • PK-10571 - Drug Profile
    • PLX-PAD - Drug Profile
    • PT-2977 - Drug Profile
    • QCC-374 - Drug Profile
    • R-190 - Drug Profile
    • R-197 - Drug Profile
    • ralinepag - Drug Profile
    • RT-234 - Drug Profile
    • SAR-7334 - Drug Profile
    • selegiline + PDE-5 Inhibitor - Drug Profile
    • selexipag - Drug Profile
    • selonsertib - Drug Profile
    • SER-100 - Drug Profile
    • sirolimus albumin-bound - Drug Profile
    • Small Molecule for Pulmonary Arterial Hypertension - Drug Profile
    • Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile
    • Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension - Drug Profile
    • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile
    • Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile
    • Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile
    • Small Molecules to Inhibit MetAP-II for Oncology, Immunology, Infectious Disease, Cardiovascular and Metabolic Disorders - Drug Profile
    • SPI-054 - Drug Profile
    • SPI-183 - Drug Profile
    • SUD-004 - Drug Profile
    • Synthetic Peptide to Inhibit NADPH Oxidase for Pulmonary Hypertension and Cardiovascular Disease - Drug Profile
    • tacrolimus - Drug Profile
    • tadalafil - Drug Profile
    • tiprelestat - Drug Profile
    • TPN-171 - Drug Profile
    • TR-422 - Drug Profile
    • treprostinil - Drug Profile
    • treprostinil diolamine - Drug Profile
    • TXA-127 - Drug Profile
    • udenafil - Drug Profile
    • VR-876 - Drug Profile
  • Pulmonary Hypertension - Recent Pipeline Updates
  • Pulmonary Hypertension - Dormant Projects
  • Pulmonary Hypertension - Discontinued Products
  • Pulmonary Hypertension - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pulmonary Hypertension, H2 2015
  • Number of Products under Development for Pulmonary Hypertension - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Pulmonary Hypertension - Pipeline by Actelion Ltd, H2 2015
  • Pulmonary Hypertension - Pipeline by APT Therapeutics, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Asahi Kasei Pharma Corp., H2 2015
  • Pulmonary Hypertension - Pipeline by Ascendis Pharma A/S, H2 2015
  • Pulmonary Hypertension - Pipeline by Bayer AG, H2 2015
  • Pulmonary Hypertension - Pipeline by Bial - Portela & Ca, S.A., H2 2015
  • Pulmonary Hypertension - Pipeline by Biolab Sanus Farmaceutica Ltda., H2 2015
  • Pulmonary Hypertension - Pipeline by Cardioxyl Pharmaceuticals, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Carolus Therapeutics, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Celsion Corporation, H2 2015
  • Pulmonary Hypertension - Pipeline by Complexa, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Corridor Pharmaceuticals Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Cytokinetics, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Eli Lilly and Company, H2 2015
  • Pulmonary Hypertension - Pipeline by Gilead Sciences, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
  • Pulmonary Hypertension - Pipeline by Insmed Incorporated, H2 2015
  • Pulmonary Hypertension - Pipeline by Kowa Company, Ltd., H2 2015
  • Pulmonary Hypertension - Pipeline by Lacer, S.A., H2 2015
  • Pulmonary Hypertension - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
  • Pulmonary Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2015
  • Pulmonary Hypertension - Pipeline by miRagen Therapeutics, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
  • Pulmonary Hypertension - Pipeline by Novartis AG, H2 2015
  • Pulmonary Hypertension - Pipeline by Peloton Therapeutics, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by PharmaIN Corporation, H2 2015
  • Pulmonary Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Pluristem Therapeutics Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Proteo, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Pulmokine, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Respira Therapeutics, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Sagene Pharmaceuticals, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Sanofi, H2 2015
  • Pulmonary Hypertension - Pipeline by Selten Pharma, Inc, H2 2015
  • Pulmonary Hypertension - Pipeline by Serodus ASA, H2 2015
  • Pulmonary Hypertension - Pipeline by Silence Therapeutics Plc, H2 2015
  • Pulmonary Hypertension - Pipeline by Sinoxa Pharma GmbH, H2 2015
  • Pulmonary Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by Suda Ltd, H2 2015
  • Pulmonary Hypertension - Pipeline by Toray Industries, Inc., H2 2015
  • Pulmonary Hypertension - Pipeline by VBS Pharmaceuticals, H2 2015
  • Pulmonary Hypertension - Pipeline by Vectura Group Plc, H2 2015
  • Pulmonary Hypertension - Pipeline by Vicore Pharma AB, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Pulmonary Hypertension Therapeutics - Recent Pipeline Updates, H2 2015
  • Pulmonary Hypertension - Dormant Projects, H2 2015
  • Pulmonary Hypertension - Dormant Projects (Contd..1), H2 2015
  • Pulmonary Hypertension - Dormant Projects (Contd..2), H2 2015
  • Pulmonary Hypertension - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Pulmonary Hypertension, H2 2015
  • Number of Products under Development for Pulmonary Hypertension - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top